{"id":234392,"date":"2023-04-18T10:15:06","date_gmt":"2023-04-18T08:15:06","guid":{"rendered":"https:\/\/fefac.cat\/empresarial\/?p=234392"},"modified":"2023-04-18T10:17:14","modified_gmt":"2023-04-18T08:17:14","slug":"escopolamina-reaccions-adverses-confusio-butilescopolamina","status":"publish","type":"post","link":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/","title":{"rendered":"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0"},"content":{"rendered":"\n<p>El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l&#8217;administraci\u00f3 err\u00f2nia d&#8217;escopolamina en lloc de butilescopolamina. Els pacients afectats van requerir assist\u00e8ncia m\u00e8dica. Els errors detectats indiquen que la confusi\u00f3 es pot presentar en la prescripci\u00f3, en la dispensaci\u00f3 i en l&#8217;administraci\u00f3 del medicament.<\/p>\n\n\n\n<p>La butilescopolamina bromur (en el passat denominada escopolamina butilbromur), per la seva estructura qu\u00edmica d&#8217;una sal d&#8217;amoni quatern\u00e0ria, no travessa la barrera hematoencef\u00e0lica. Est\u00e0 indicada per al tractament d&#8217;espasmes aguts del tracte gastrointestinal, biliar i genitourinari (consultar la fitxa t\u00e8cnica per a informaci\u00f3 detallada). L&#8217;escopolamina hidrobromur, en canvi, t\u00e9 estructura d&#8217;amina terci\u00e0ria, pel que travessa la barrera hematoencef\u00e0lica i est\u00e0 indicada com a premedicaci\u00f3 en l&#8217;anest\u00e8sia per a reduir la salivaci\u00f3 excessiva i les secrecions del tracte respiratori (consultar la fitxa t\u00e8cnica per a informaci\u00f3 detallada).<\/p>\n\n\n\n<p>La denominaci\u00f3 molt similar dels dos principis actius els fa susceptibles de confusi\u00f3. No obstant aix\u00f2, les seves indicacions i dosatge s\u00f3n molt diferents. Poden consultar-se les fitxes t\u00e8cniques dels diferents medicaments en el <strong><em><span style=\"text-decoration: underline\"><a href=\"https:\/\/cima.aemps.es\/cima\/publico\/home.html\" target=\"_blank\" rel=\"noreferrer noopener\">Centre d&#8217;Informaci\u00f3 En l\u00ednia de Medicaments de l&#8217;AEMPS (CIM).<\/a><\/span><\/em><\/strong><\/p>\n\n\n\n<p>L&#8217;administraci\u00f3 per error d&#8217;escopolamina a dosi de butilescopolamina suposa una sobredosi que pot provocar reaccions adverses anticolin\u00e8rgiques a nivell del sistema nervi\u00f3s central amb conseq\u00fc\u00e8ncies greus. Els signes i s\u00edmptomes caracter\u00edstics de la sobredosi d&#8217;escopolamina s\u00f3n cefalea, n\u00e0usees, v\u00f2mits, visi\u00f3 borrosa, confusi\u00f3, desorientaci\u00f3, p\u00e8rdua de mem\u00f2ria i al\u00b7lucinacions.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Recomanacions per a professionals sanitaris<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Parar esment detallada a la possible confusi\u00f3 entre escopolamina i butilescopolamina, tant en la prescripci\u00f3 com en la dispensaci\u00f3 i administraci\u00f3 del medicament.<\/li>\n\n\n\n<li>Abans de dispensar o d&#8217;administrar el medicament, verificar el nom, dosi, forma farmac\u00e8utica i indicaci\u00f3 corresponents.<\/li>\n\n\n\n<li>Facilitar la diferenciaci\u00f3 entre els medicaments amb noms similars en totes les etapes de la utilitzaci\u00f3 del medicament.<\/li>\n\n\n\n<li>Davant l&#8217;eventual sospita de sobredosi d&#8217;escopolamina, seguir les recomanacions de tractament (fitxa t\u00e8cnica apartat 4.9: sobredosi).<\/li>\n<\/ul>\n\n\n\n<p>Font d&#8217;informaci\u00f3: AEMPS<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l&#8217;administraci\u00f3 err\u00f2nia d&#8217;escopolamina en lloc de butilescopolamina. Els pacients afectats van requerir assist\u00e8ncia m\u00e8dica. Els errors detectats indiquen que la confusi\u00f3 es pot presentar en la prescripci\u00f3, en la dispensaci\u00f3 i en l&#8217;administraci\u00f3 del medicament.<\/p>\n","protected":false},"author":2313,"featured_media":234393,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2066,10,11,101],"tags":[1127,1128,2517],"class_list":["post-234392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-categoria-actualitat","category-empresarials","category-fefac","category-sanitaria","tag-farmacia","tag-farmaceutic","tag-escopolamina"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0<\/title>\n<meta name=\"description\" content=\"El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l&#039;administraci\u00f3 err\u00f2nia d&#039;escopolamina en lloc de butilescopolamina.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0\" \/>\n<meta property=\"og:description\" content=\"El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l&#039;administraci\u00f3 err\u00f2nia d&#039;escopolamina en lloc de butilescopolamina.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/\" \/>\n<meta property=\"og:site_name\" content=\"FEFAC\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T08:15:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T08:17:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2023\/04\/medicaments-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"lclavijo@afb.cat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"lclavijo@afb.cat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/\"},\"author\":{\"name\":\"lclavijo@afb.cat\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/6ac15c94fb359972b6bfa9c752486744\"},\"headline\":\"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0\",\"datePublished\":\"2023-04-18T08:15:06+00:00\",\"dateModified\":\"2023-04-18T08:17:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/\"},\"wordCount\":361,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/medicaments-scaled.jpg\",\"keywords\":[\"farm\u00e0cia\",\"farmac\u00e8utic\",\"escopolamina\"],\"articleSection\":[\"Actualitat\",\"Empresarials\",\"FEFAC\",\"Sanit\u00e0ria\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/\",\"name\":\"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/medicaments-scaled.jpg\",\"datePublished\":\"2023-04-18T08:15:06+00:00\",\"dateModified\":\"2023-04-18T08:17:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/6ac15c94fb359972b6bfa9c752486744\"},\"description\":\"El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l'administraci\u00f3 err\u00f2nia d'escopolamina en lloc de butilescopolamina.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/medicaments-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/medicaments-scaled.jpg\",\"width\":2560,\"height\":1600,\"caption\":\"Pharmacist scanning barcode of medicine drug in a pharmacy drugstore\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/escopolamina-reaccions-adverses-confusio-butilescopolamina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\",\"name\":\"FEFAC\",\"description\":\"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/6ac15c94fb359972b6bfa9c752486744\",\"name\":\"lclavijo@afb.cat\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/author\\\/laura-2\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0","description":"El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l'administraci\u00f3 err\u00f2nia d'escopolamina en lloc de butilescopolamina.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/","og_locale":"ca_ES","og_type":"article","og_title":"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0","og_description":"El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l'administraci\u00f3 err\u00f2nia d'escopolamina en lloc de butilescopolamina.","og_url":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/","og_site_name":"FEFAC","article_published_time":"2023-04-18T08:15:06+00:00","article_modified_time":"2023-04-18T08:17:14+00:00","og_image":[{"width":2560,"height":1600,"url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2023\/04\/medicaments-scaled.jpg","type":"image\/jpeg"}],"author":"lclavijo@afb.cat","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"lclavijo@afb.cat","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#article","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/"},"author":{"name":"lclavijo@afb.cat","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/6ac15c94fb359972b6bfa9c752486744"},"headline":"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0","datePublished":"2023-04-18T08:15:06+00:00","dateModified":"2023-04-18T08:17:14+00:00","mainEntityOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/"},"wordCount":361,"commentCount":0,"image":{"@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2023\/04\/medicaments-scaled.jpg","keywords":["farm\u00e0cia","farmac\u00e8utic","escopolamina"],"articleSection":["Actualitat","Empresarials","FEFAC","Sanit\u00e0ria"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/","url":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/","name":"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#primaryimage"},"image":{"@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2023\/04\/medicaments-scaled.jpg","datePublished":"2023-04-18T08:15:06+00:00","dateModified":"2023-04-18T08:17:14+00:00","author":{"@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/6ac15c94fb359972b6bfa9c752486744"},"description":"El Sistema Espanyol de Farmacovigil\u00e0ncia (SEFV-H) ha rebut cinc casos de reaccions adverses greus relacionats amb l'administraci\u00f3 err\u00f2nia d'escopolamina en lloc de butilescopolamina.","breadcrumb":{"@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#primaryimage","url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2023\/04\/medicaments-scaled.jpg","contentUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2023\/04\/medicaments-scaled.jpg","width":2560,"height":1600,"caption":"Pharmacist scanning barcode of medicine drug in a pharmacy drugstore"},{"@type":"BreadcrumbList","@id":"https:\/\/fefac.cat\/empresarial\/escopolamina-reaccions-adverses-confusio-butilescopolamina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fefac.cat\/empresarial\/"},{"@type":"ListItem","position":2,"name":"Escopolamina: reaccions adverses per confusi\u00f3 amb\u00a0butilescopolamina\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/fefac.cat\/empresarial\/#website","url":"https:\/\/fefac.cat\/empresarial\/","name":"FEFAC","description":"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fefac.cat\/empresarial\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/6ac15c94fb359972b6bfa9c752486744","name":"lclavijo@afb.cat","url":"https:\/\/fefac.cat\/empresarial\/author\/laura-2\/"}]}},"_links":{"self":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/234392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/users\/2313"}],"replies":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/comments?post=234392"}],"version-history":[{"count":0,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/234392\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media\/234393"}],"wp:attachment":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media?parent=234392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/categories?post=234392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/tags?post=234392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}